EU/3/16/1729

About

On 29 August 2016, orphan designation (EU/3/16/1729) was granted by the European Commission to Lucane Pharma SA, France, for sodium benzoate for the treatment of lysinuric protein intolerance.

Key facts

Active substance
Sodium benzoate
Disease / condition
Treatment of lysinuric protein intolerance
Date of decision
29/08/2016
Outcome
Positive
Orphan decision number
EU/3/16/1729

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Lucane Pharma SA
172 rue de Charonne
75011 Paris
France
Tel. +33 1 53 86 87 53
Fax +33 1 47 34 56 72
E-mail: info@lucanepharma.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating